All In Biotech

Drug Trial Radar · NCT05994534

PK and PD Study of NPI-001 and Cysteamine Bitartrate

A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Oct 29, 2023

Primary completion

May 26, 2026

Study completion May 26, 2026

Sponsor

Lead sponsor
Nacuity Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety, pharmacokinetics, and pharmacodynamics of NPI-001 oral solution in cystinosis patients compared with cysteamine.

Conditions

  • Cystinosis

Interventions

  • Cysteamine BitartrateDrug

    Single dose, tablets at current therapeutic dose

  • N-Acetylcysteine AmideDrug

    Single dose, oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of Cystine Levels Over TimeTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital at Westmead

    Westmead, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.